Editas Medicine, Inc. (EDIT) Stock Price & How to Invest

Editas Medicine (EDIT) is a clinical-stage biotechnology company developing gene-editing medicines based on CRISPR technology. It aims to treat serious diseases by making precise changes to DNA, and has shifted its strategy toward in vivo genomic medicines, which edit genes directly inside the body, after earlier work on ex vivo cell therapies. Its lead program, EDIT-401, is an experimental in vivo therapy aimed at lowering cholesterol-related risk that is moving toward its first human trial. Editas is unprofitable and pre-commercial: it has no approved products and generates only modest revenue, mostly from licensing its intellectual property, while spending heavily on research and burning cash each quarter. As of early 2026 the company reported roughly $124 million in cash and a projected runway into the third quarter of 2027, alongside workforce reductions meant to focus spending on its lead programs. Headquartered in Cambridge, Massachusetts, Editas is a highly speculative, science-stage company whose value depends almost entirely on unproven clinical results, financing, and the broader competition to turn CRISPR editing into approved therapies. Nothing here is investment advice.

Editas is a highly speculative, clinical-stage biotech with no approved products and no meaningful product revenue, and it loses money and burns cash every quarter. Its value depends on binary clinical-trial outcomes: a single disappointing data readout, safety problem, or regulatory setback can cut the stock sharply, and a failed lead program could erase most of its value. Because it is unprofitable, it will likely need to raise more money by selling stock (diluting existing shareholders), taking on debt, or signing partnerships, and financing may not be available on good terms. Gene editing is scientifically and regulatory complex, with long timelines and uncertain safety. Competition from CRISPR Therapeutics, Intellia, Beam, and larger pharma is intense, and rivals may reach the market first or with better therapies. Intellectual-property disputes over CRISPR are ongoing. The stock is volatile, can trade far below past highs, and is unsuitable for investors who cannot tolerate the risk of large or total loss.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Editas Medicine, Inc.'s investor relations page or your broker.

• Stage: clinical-stage, pre-commercial (no approved products)
• Profitability: unprofitable; ongoing net losses and cash burn
• Revenue (TTM): minimal, mainly licensing (Q1 2026 ~$2.8M)
• Net loss (Q1 2026): ~$25 million (narrowed from ~$76M a year earlier)
• Cash and equivalents: ~$124 million as of March 31, 2026
• Cash runway (company guidance): projected into the third quarter of 2027
• Lead program: EDIT-401, in vivo cholesterol-lowering (first-in-human planned 2026)
• Dividend: none; reinvests all capital into research

Editas cannot be valued on normal earnings measures because it is pre-revenue and unprofitable, so metrics like P/E do not apply. Its market value reflects investor expectations about the future success of unproven clinical programs, its cash position and burn rate, and the value of its CRISPR intellectual property, rather than current profits. Cash runway matters because an unprofitable biotech that runs low on cash typically must raise money by issuing new shares, which dilutes existing holders. All figures are approximate, are drawn from a fast-changing clinical-stage company, and can change quickly; verify current numbers before relying on them.

There are three common ways to get EDIT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so EDIT sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where EDIT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Editas Medicine (EDIT) is a clinical-stage CRISPR gene-editing company with a promising science story but no approved products, ongoing losses, and continuous cash burn. Its value rests almost entirely on early clinical results from programs like EDIT-401, its ability to keep financing itself, and the intensely competitive race to commercialize gene editing. It is a highly speculative, high-risk position that can swing violently on trial data, not a stable holding, and it may fall sharply or lose most of its value if programs fail or funding tightens.

Whether EDIT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EDIT a buy?, and where the stock could go from here in the EDIT stock forecast.

For income investors, whether EDIT pays a dividend and how the payout looks is covered in does EDIT pay a dividend?